Vivos Therapeutics (VVOS) Free Cash Flow Growth (3y) (2023 - 2026)
Vivos Therapeutics (VVOS) Free Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 9.23% |
| 10 | Vivos Therapeutics | 4.94 Mn | 3.14 Mn | 2.95 Mn | -5.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.80% |
| Dec 31, 2025 | -36.31% |
| Sep 30, 2025 | 11.51% |
| Jun 30, 2025 | 6.15% |
| Mar 31, 2025 | 14.17% |
| Dec 31, 2024 | 11.58% |
| Sep 30, 2024 | 0.84% |
| Jun 30, 2024 | 14.61% |
| Mar 31, 2024 | 13.52% |
| Dec 31, 2023 | 2.37% |
| Sep 30, 2023 | -51.06% |
| Jun 30, 2023 | -50.90% |
| Mar 31, 2023 | -100.98% |